Click on a filter below to refine your search. Remove a filter to broaden your search.
No significant difference was seen in hospitalization for pneumonia or influenza or in hospitalization for any cause or mortality.
The changes include a recommendation for all adults to receive a dose of the new COVID-19 vaccine and RSV vaccination.
Rates were slightly higher at 42 days for those receiving the Pfizer versus Moderna vaccine.
Changes include a new section relating to COVID-19 vaccines and the addition of a newly licensed vaccine for hepatitis B.
The incidence of shoulder conditions per 10,000 vaccinations was 1.22 for adults (age 18 years or older) and 0.05 for children (age 3 to 17 years).
Those who are partially vaccinated and unvaccinated face the same increased risk, whereas boosted and fully vaccinated adults fare best.
Vaccine hesitancy varied considerably; 12.1% of vaccinated individuals were hesitant about booster doses.
Individuals with breakthrough infection have an increased risk for death and postacute sequelae compared with contemporary controls.
No increase was seen in the incidence of myocardial infarction, stroke or pulmonary embolism among those aged 75 years or older in France.
An efficacy of 92% was found among at-risk COVID-19-unvaccinated individuals with type 1 diabetes.